The biology of metastases in pediatric sarcomas

Cancer Journal

Volumn 11, Issue 4, 2005, Pages 306-313

  Krishnan, Kartik ^a   Khanna, Chand ^a   Helman, Lee J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Metastasis; Models; Sarcoma

Indexed keywords

BEVACIZUMAB;

ANOIKIS; CANCER CELL; CANCER SURVIVAL; CELL CYCLE ARREST; CELL PROLIFERATION; CLINICAL TRIAL; EWING SARCOMA; EXTRACELLULAR MATRIX; HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RHABDOMYOSARCOMA; SOLID TUMOR; TREATMENT OUTCOME; TUMOR GROWTH; BIOLOGICAL MODEL; PATHOLOGY; PATHOPHYSIOLOGY; SARCOMA;

HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SARCOMA;

EID: 33749542027     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200507000-00006     Document Type: Review

References (68)

1. Sweetnam R. The surgical management of primary osteosarcoma. Clin Orthop Relat Res 1975;Sept:57-64.
2. Link MP, Goorin AM, Miser AW et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986;314:1600-1606.
3. Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology, 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2002.
4. Ferrari S, Bacci G, Picci P et al. Long-term follow-up and postrelapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol 1997;8:765-771.
5. Ferrari S, Briccoli A, Mercuri M et al. Postrelapse survival in osteosarcoma of the extremities: prognostic factors for longterm survival. J Clin Oncol 2003;21:710-715.
6. Hawkins DS, Arndt CA. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer 2003;98:2447-2456.
7. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev Cancer 2003;3:921-930.
8. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 1997;89:1260-1270.
9. Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev 2004;23:101-117.
10. Wagenaar-Miller RA, Gorden L, Matrisian LM. Matrix metalloproteinases in colorectal cancer: is it worth talking about? Cancer Metastasis Rev 2004;23:119-135.
11. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295:2387-2392.
12. Albini A, Melchiori A, Santi L et al. Tumor cell invasion inhibited by TIMP-2. J Natl Cancer Inst 1991;83:775-779.
13. Baker AH, George SJ, Zaltsman AB et al. Inhibition of invasion and induction of apoptotic cell death of cancer cell lines by overexpression of TIMP-3. Br J Cancer 1999;79:1347-1355.
14. Aljada IS, Ramnath N, Donohue K et al. Upregulation of the tissue inhibitor of metalloproteinase-1 protein is associated with progression of human non-small-cell lung cancer. J Clin Oncol 2004;22:3218-3229.
15. Zeng ZS, Cohen AM, Zhang ZF et al. Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1995;1:899-906.
16. Frisch SM, Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994;124:619-626.
17. Grossmann J. Molecular mechanisms of "detachment-induced apoptosis-anoikis." Apoptosis 2002;7:247-260.
18. Guo W, Giancotti FG. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 2004;5:816-826.
19. Fukata M, Kaibuchi K. Rho-family GTPases in cadherin-mediated cell-cell adhesion. Nat Rev Mol Cell Biol 2001;2:887-897.
20. Seftor RE, Seftor EA, Gehlsen KR et al. Role of the alpha v beta 3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992;89:1557-1561.
21. Zheng DQ, Woodard AS, Fornaro M et al. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 1999;59:1655-1664.
22. Ruoslahti E, Reed JC. Anchorage dependence, integrins, and apoptosis. Cell 1994;77:477-478.
23. Douma S, Van Laar T, Zevenhoven J et al. Suppression of anoikis and induction of metastasis by the neurotrophic receptor trkb. Nature 2004;430:1034-1039.
24. Beavon IR. The e-cadherin-catenin complex in tumour metastasis: structure, function and regulation. Eur J Cancer 2000;36:1607-1620.
25. Flanagan SP. "Nude", a new hairless gene with pleiotropic effects in the mouse. Genet Res 1966;8:295-309.
26. Pantelouris EM. Absence of thymus in a mouse mutant. Nature 1968;217:370-371.
27. Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998;95:7556-7561.
28. Garrido F, Ruiz-Cabello F, Cabrera T et al. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 1997;18:89-95.
29. Schreiber H, Wu TH, Nachman J et al. Immunodominance and tumor escape. Semin Cancer Biol 2002;12:25-31.
30. Hofbauer GF, Kamarashev J, Geertsen R et al. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution. Melanoma Res 1998;8:337-343.
31. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-beta. Annu Rev Immunol 1998;16:137-161.
32. Kirkbride KC, Blobe GC. Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy. Expert Opin Biol Ther 2003;3:251-261.
33. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002;3:999-1005.
34. Mocellin S, Mandruzzato S, Bronte V et al. Part I: vaccines for solid tumours. Lancet Oncol 2004;5:681-689.
35. Qazilbash MH, Wieder E, Rios R et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia (abstract). Blood 2004;104:#259.
36. Paget S. Distribution of secondary growths in cancer of the breast. Lancet 1889;133:571-573.
37. Fidler IJ. The organ microenvironment and cancer metastasis. Differentiation 2002;70:498-505.
38. Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMS in cancer. Nat Rev Cancer 2004;4:118-132.
39. Cavallaro U, Niedermeyer J, Fuxa M et al. N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling. Nat Cell Biol 2001;3:650-657.
40. Okegawa T, Li Y, Pong RC et al. Cell adhesion proteins as tumor suppressors. J Urol 2002;167:1836-1843.
41. Martin TA, Harrison G, Mansel RE et al. The role of the CD44/ezrin complex in cancer metastasis. Crit Rev Oncol Hematol 2003;46:165-186.
42. Balkwill F. Cancer and the chemokine network. Nat Rev Cancer 2004;4:540-550.
43. Geminder H, Sagi-Assif O, Goldberg L et al. A possible role for CXCR4 and its ligand, the CXC chemokine stromal cell-derived factor-1, in the development of bone marrow metastases in neuroblastoma. J Immunol 2001;167:4747-4757.
44. Robinson SC, Scott KA, Wilson JL et al. A chemokine receptor antagonist inhibits experimental breast tumor growth. Cancer Res 2003;63:8360-8365.
45. Rubin JB, Kung AL, Klein RS et al. A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors. Proc Natl Acad Sci USA 2003;100:13513-13518.
46. Sugarbaker EV, Ketcham AS, Cohen AM. Studies of dormant tumor cells. Cancer 1971;28:545-552.
47. Goodison S, Kawai K, Hihara J et al. Prolonged dormancy and site-specific growth potential of cancer cells spontaneously disseminated from nonmetastatic breast tumors as revealed by labeling with green fluorescent protein. Clin Cancer Res 2003;9:3808-3814.
48. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995;1:149-153.
49. O'Reilly MS, Holmgren L, Chen C et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2:689-692.
50. Bayko L, Rak J, Man S et al. The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor. Angiogenesis 1998;2:203-217.
51. Schirrmacher V. T-cell immunity in the induction and maintenance of a tumour dormant state. Semin Cancer Biol 2001;11:285-295.
52. Farrar JD, Katz KH, Windsor J et al. Cancer dormancy. VII: a regulatory role for CD8+ T cells and IFN-gamma in establishing and maintaining the tumor-dormant state. J Immunol 1999;162:2842-2849.
53. Aguirre-Ghiso JA, Estrada Y, Liu D et al. ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Res 2003;63:1684-1695.
54. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739.
55. Lopez-Ocejo O, Viloria-Petit A, Bequet-Romero M et al. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner. Oncogene 2000;19:4611-4620.
56. Rak J, Mitsuhashi Y, Sheehan C et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res 2000;60:490-498.
57. Gefitinib (iressa) lung cancer ISEL trial shows no overall survival advantage in a highly refractory population. Wilmington, DE: AstraZeneca Press Release, 2004.
58. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
59. Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
60. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436.
61. Sikder H, Huso DL, Zhang H et al. Disruption of Id1 reveals major differences in angiogenesis between transplanted and autochthonous tumors. Cancer Cell 2003;4:291-299.
62. Alani RM, Silverthorn CF, Orosz K. Tumor angiogenesis in mice and men. Cancer Biol Ther 2004;3:498-500.
63. Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005;26:513-523.
64. Khanna C, Khan J, Nguyen P et al. Metastasis-associated differences in gene expression in a murine model of osteosarcoma. Cancer Res 2001;61:3750-3759.
65. Khanna C, Wan X, Bose S et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 2004;10:182-186.
66. Yu Y, Khan J, Khanna C et al. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein six-1 as key metastatic regulators. Nat Med 2004;10:175-181.
67. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-348.
68. Ramaswamy S, Ross KN, Lander ES et al. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003;33:49-54.